As a clinically relevant example, it is unclear whether in patients with an existing tumour-specific T cell response combined blockade of PD-1 and CTLA-4 will be preferable over single agent PD-1 blockade, both because of the toxicity associated with (combination) treatment and the very significant treatment costs of cancer immunotherapies. This evidence concerns the gene CTLA4 and neoplasm.